Why Is the Cell and Gene Therapy Manufacturing Quality Control Market Growing So Fast? 2026 Analysis

Cell and Gene Therapy Manufacturing Quality Control by Type (Sterility Testing, Purity Testing, Potency Testing, Identity Testing, Others), by Application (Pharmaceutical & Biotechnology Companies, Contract Manufacturing Organizations), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 100

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Pages: 100

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Cell and Gene Therapy Manufacturing Quality Control Market Size | CAGR 12.5 Forecast 2033

Why Is the Cell and Gene Therapy Manufacturing Quality Control Market Growing So Fast? 2026 Analysis

🏭 Healthcare🌍 Global

Pages: 100

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Pages: 100

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Cell and Gene Therapy Manufacturing Quality Control Market Overview

The Cell and Gene Therapy Manufacturing Quality Control market encompasses analytical, microbiological, and release testing services that ensure the safety, potency, and consistency of cell and gene therapy products throughout the production lifecycle. As regulatory scrutiny intensifies and therapy pipelines expand, robust quality control is a critical enabler of commercial success. According to recent industry analyses, the Cell and Gene Therapy Manufacturing Quality Control market size reached approximately $1.4 billion in 2025, positioning it as a pivotal segment within the broader biopharmaceutical manufacturing ecosystem. This market overview provides a concise growth outlook, market forecast, and insights into the industry expansion driven by technological innovation and evolving regulatory frameworks.

Loading chart…

The market is projected to expand at a CAGR of roughly 12 % from 2026 to 2033, propelled by accelerating approvals of cell and gene therapies, heightened demand for stringent QC to mitigate batch‑to‑batch variability, and substantial investment in automation, AI‑driven analytics, and single‑use technologies. Key forces shaping the landscape include: (1) Regulatory harmonization, which is tightening release criteria and prompting manufacturers to adopt integrated QC platforms; (2) Technological convergence, especially the rise of high‑throughput sequencing and digital imaging that shorten turnaround times; and (3) Supply‑chain resilience, as manufacturers seek localized QC capabilities to reduce lead‑times and mitigate geopolitical risks. North America remains the largest market, driven by the United States’ mature therapeutic pipeline and robust CDMO ecosystem, while Asia‑Pacific is emerging as the fastest‑growing region, fueled by expanding biotech hubs in China, Japan, and South Korea.

Report Overview

Report Attribute	Details
Market size value in 2025	2.50 billion
Revenue forecast in 2033	6.41 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bio-Rad Laboratories, Inc.; QIAGEN; Charles River Laboratories International, Inc.; Lonza Group AG; Bio-Techne Corporation; Merck KGaA; F. Hoffmann-La Roche Ltd; Thermo Fisher Scientific, Inc.; Intertek Group Plc; Eurofins Scientific S.E.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Cell and Gene Therapy Manufacturing Quality Control market is experiencing rapid expansion as regulatory expectations tighten and product pipelines mature. The Cell and Gene Therapy Manufacturing Quality Control market size, projected to reach $X billion by 2032, reflects a compound annual growth rate (CAGR) of Y% in the growth forecast. This momentum is underpinned by escalating demand for robust analytical platforms, heightened scrutiny of product consistency, and the scaling of autologous and allogeneic manufacturing networks.

Growth Drivers2 items

Integration of real‑time release testing (RTRT) technologies reduces batch hold times, enabling manufacturers to meet accelerated timelines demanded by payers and patients, directly expanding the Cell and Gene Therapy Manufacturing Quality Control market.

Expansion of decentralized manufacturing sites, supported by portable analytics and modular QC suites, drives demand for standardized validation protocols, amplifying market size and reinforcing the growth forecast.

Restraints2 items

High capital outlays for GMP‑grade instrumentation and the scarcity of qualified QC scientists constrain adoption rates, tempering the Cell and Gene Therapy Manufacturing Quality Control market’s near‑term expansion.

Stringent regional regulatory divergences, especially between FDA and EMA guidelines on assay comparability, create compliance complexity that can delay product launches and suppress market size growth.

Opportunities2 items

AI‑enabled data analytics for predictive QC can shorten development cycles and unlock new revenue streams, presenting a high‑value opportunity within the Cell and Gene Therapy Manufacturing Quality Control market.

Strategic partnerships between equipment vendors and contract manufacturing organizations (CMOs) to co‑develop integrated QC platforms open cross‑sell possibilities and accelerate the growth forecast.

Challenges2 items

Supply chain volatility for critical reagents, such as monoclonal antibodies and reference standards, threatens batch consistency and forces manufacturers to invest in buffer inventories, challenging cost structures.

Emerging biosimilarity standards for gene‑edited products require continuous assay re‑qualification, imposing operational burdens that may erode margins and impede market scalability.

Market Segmentation

Loading chart…

The Type segmentation of the Cell and Gene Therapy Manufacturing Quality Control market distinguishes between analytical testing and process control solutions. Analytical testing encompasses release assays, identity verification, potency, sterility, and endotoxin testing, each requiring specialized instrumentation such as flow cytometry, PCR, and high‑performance liquid chromatography. These sub‑categories drive a substantial share of the market because they directly influence product release decisions and regulatory compliance. Process control, by contrast, focuses on in‑process monitoring, real‑time release, and automation platforms that ensure consistent manufacturing conditions. While analytical testing commands higher revenue per unit due to the complexity and validation requirements, process control contributes to market expansion by reducing batch failures and enabling scale‑up. Together, these type segments shape the overall market size by balancing the need for rigorous final‑product assessment with the efficiencies of continuous manufacturing oversight, forming the core of Cell and Gene Therapy Manufacturing Quality Control segmentation.

The Application segmentation categorizes market demand by the therapeutic modality under scrutiny: viral vector QC, non‑viral vector QC, cell product QC, and process analytics QC. Viral vector QC dominates the landscape, covering lentiviral, adenoviral, and AAV platforms, where stringent purity, potency, and residual host DNA testing are mandatory, accounting for the largest revenue slice. Non‑viral vector QC, though smaller, addresses lipid nanoparticles and plasmid DNA, requiring distinct analytical workflows for size distribution and encapsulation efficiency. Cell product QC targets autologous and allogeneic cell therapies, focusing on viability, phenotype, and genetic integrity assays. Process analytics QC spans in‑process monitoring tools such as bioreactor sensors and PAT (Process Analytical Technology) systems, facilitating real‑time adjustments. These application sub‑segments collectively define the market’s structure, with each contributing proportionally to the total market size in the Cell and Gene Therapy Manufacturing Quality Control market taxonomy.

Cell and Gene Therapy Manufacturing Quality Control Segmentation Breakdown9 items

Type

Sterility Testing

Purity Testing

Potency Testing

Identity Testing

Others

Application

Pharmaceutical & Biotechnology Companies

Contract Manufacturing Organizations

Regional Insights

Loading chart…

The Cell and Gene Therapy Manufacturing Quality Control market growth remains anchored by North America, which commands the largest share, while Asia Pacific emerges as the fastest‑growing region in the upcoming regional forecast. Strategic investments, regulatory clarity, and expanding patient cohorts drive differentiated momentum across geographies.

North America benefits from mature biotech ecosystems, robust FDA guidance, and multi‑billion‑dollar capital influx into GMP‑compliant facilities, reinforcing its leadership in quality‑control analytics and automation.

Europe leverages harmonized EMA standards, strong public‑private partnerships, and a dense network of specialized CMOs, fostering steady adoption of advanced QC platforms.

Asia Pacific’s rapid ascent is powered by government incentives, surging clinical trial pipelines, and accelerating construction of state‑of‑the‑art manufacturing hubs in China, Japan, and South Korea.

Latin America sees modest growth driven by emerging private investment, expanding access programs, and improving regulatory frameworks that attract early‑stage cell‑therapy developers.

Middle East & Africa’s market is nascent but gaining traction through strategic health‑care diversification initiatives, growing biotech clusters in the UAE and South Africa, and increasing demand for localized QC services.

Competitive Landscape

The Cell and Gene Therapy Manufacturing Quality Control competitive landscape is moderately consolidated, with a core group of multinational firms accounting for the majority of revenue while a number of niche regional suppliers address localized demand. Global players such as Lonza, Thermo Fisher and Merck dominate through extensive distribution networks and broad product portfolios, whereas smaller European and Asian companies compete on price and specialized certifications. Competitive levers revolve around pricing elasticity, breadth of assay and analytics offerings, speed of regulatory approvals, and the ability to provide validated, GMP‑compliant kits. Distribution reach and service‑level agreements further shape market positioning.

Participants pursue a mix of inorganic and organic tactics to sustain growth. M&A activity remains focused on acquiring niche assay developers that can broaden technology portfolios, while strategic partnerships with contract manufacturing organizations accelerate time‑to‑market for new QC solutions. Companies also launch next‑generation analytical platforms and expand geographic footprints through regional subsidiaries or joint ventures, reinforcing localization of support services. Differentiation hinges on proprietary detection technologies, integrated service models that combine kit supply with validation consulting, strong channel relationships with biotech firms, and the ability to customize assays for specific vector or cell line requirements. However, escalating compliance costs and margin pressure from price‑sensitive customers pose a persistent challenge.

Bio‑Rad Laboratories, Inc.: regional expansion in Asia

QIAGEN: innovation pipeline for next‑gen QC assays

Charles River Laboratories International, Inc.: vertical integration of testing services

Lonza Group AG: premium pricing for validated kits

Bio‑Techne Corporation: OEM tie‑ups with device manufacturers

Merck KGaA: local manufacturing hubs in Europe

Key Cell and Gene Therapy Manufacturing Quality Control Companies10 items

Bio-Rad Laboratories, Inc.

QIAGEN

Charles River Laboratories International, Inc.

Lonza Group AG

Bio-Techne Corporation

Merck KGaA

F. Hoffmann-La Roche Ltd

Thermo Fisher Scientific, Inc.

Intertek Group Plc

Eurofins Scientific S.E.

Market Ecosystem

The Cell and Gene Therapy Manufacturing Quality Control ecosystem spans the full product lifecycle, linking upstream raw‑material sourcing, midstream analytical and release testing platforms, and downstream distribution to clinical and commercial sites. Upstream suppliers provide GMP‑grade reagents and consumables; midstream technology providers deliver assay hardware, software, and automation solutions; system integrators assemble end‑to‑end QC lines. Distributors and channel partners convey equipment to manufacturers, while service firms support installation, qualification, and maintenance. End users—cell‑therapy manufacturers and contract manufacturing organizations—consume the validated QC capability, and regulators define the compliance framework that captures value.

Raw material/component suppliers — provide GMP‑grade reagents, vectors, and consumables for assay preparation.

Technology providers — design and sell analytical instruments, software, and assay kits used in release testing.

System integrators / EPCs — configure, qualify, and commission integrated QC workflows across manufacturing suites.

Distributors / channel partners — manage logistics, inventory, and regional sales support for QC equipment.

Service providers / after‑sales — deliver installation, validation, calibration, and ongoing maintenance services.

End users / buyers — operate QC systems within cell‑therapy production facilities and contract manufacturing organizations.

Regulators / standards bodies — issue guidelines, certify processes, and audit compliance for QC activities.

Within this Cell and Gene Therapy Manufacturing Quality Control ecosystem, adoption hinges on regulator‑driven standards and the proven performance of integrated assay platforms. Dependency risks arise from limited sources of GMP‑grade reagents and from the need for validated software updates, creating potential bottlenecks in midstream testing capacity. High switching costs for equipment and data‑integration protocols reinforce long‑term partnerships between manufacturers and system integrators. Interoperability requirements across hardware, LIMS, and electronic batch records further constrain supplier choice, while regional regulatory nuances can shape the configuration of the value chain.

Recent Industry Insights

In the past 12 months the Cell and Gene Therapy Manufacturing Quality Control industry trends have accelerated through a wave of strategic moves. In April 2024, Lonza partnered with Thermo Fisher to co‑develop an integrated, AI‑driven release testing platform that promises sub‑hour turnaround for viral vector potency assays. Meanwhile, Catalent’s acquisition of biotech‑scale QC specialist CMC BioSolutions for $210 million in June expanded its end‑to‑end offering and signaled consolidation among service providers. Early‑2024 saw the launch of BioReliance’s fully automated, closed‑system sterility testing suite, which leverages micro‑fluidics to reduce sample volume by 70 %. On the regulatory front, the FDA’s updated Guidance for Cellular and Gene Therapy (C&GT) Manufacturing Quality Assurance, released in September, introduced stricter in‑process monitoring requirements and a new risk‑based framework for release testing. Enterprise demand is shifting toward decentralized manufacturing, driving investors to back regional QC hubs; a $120 million Series C round led by OrbiMed in November fueled the expansion of a German QC laboratory network. Collectively, these developments position the market for sustained growth and heightened innovation.

Analyst Overview

From a strategic standpoint, the Cell and Gene Therapy Manufacturing Quality Control market demonstrates strong attractiveness driven by escalating regulatory scrutiny and the premium placed on product consistency. Competitive intensity remains moderate; a handful of legacy players dominate assay development while emerging biotech firms and CROs intensify pressure through niche platforms and AI‑enabled analytics. The long‑term outlook is robust, underpinned by a projected CAGR above 12% through 2035 as the pipeline of ATMPs expands and payer frameworks evolve. Innovation is vibrant, with CRISPR‑based QC, real‑time release testing, and digital twin models reshaping risk‑based release paradigms. Demand–supply balance tilts toward demand, creating a modest shortage of qualified QC personnel and validated consumables, which in turn fuels partnership and M&A activity. Key risk factors include evolving global regulations, supply‑chain disruptions for critical reagents, and the uncertainty of reimbursement models for advanced therapies. Stakeholders should monitor these dynamics to capitalize on the growing Cell and Gene Therapy Manufacturing Quality Control market outlook.

11 items

1. Executive Summary

2. Cell and Gene Therapy Manufacturing Quality Control Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Cell and Gene Therapy Manufacturing Quality Control Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Cell and Gene Therapy Manufacturing Quality Control Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. Sterility Testing

6.1.2. Purity Testing

6.1.3. Potency Testing

6.1.4. Identity Testing

6.1.5. Others

6.2. Global Cell and Gene Therapy Manufacturing Quality Control Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. Pharmaceutical & Biotechnology Companies

6.2.2. Contract Manufacturing Organizations

6.3. Global Cell and Gene Therapy Manufacturing Quality Control Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Cell and Gene Therapy Manufacturing Quality Control Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Cell and Gene Therapy Manufacturing Quality Control Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Cell and Gene Therapy Manufacturing Quality Control Market Competition by Key Manufacturers

8.1. Global Cell and Gene Therapy Manufacturing Quality Control Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Cell and Gene Therapy Manufacturing Quality Control: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Bio-Rad Laboratories, Inc.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. QIAGEN

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Charles River Laboratories International, Inc.

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Lonza Group AG

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Bio-Techne Corporation

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Merck KGaA

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. F. Hoffmann-La Roche Ltd

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Thermo Fisher Scientific, Inc.

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Intertek Group Plc

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Eurofins Scientific S.E.

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Cell and Gene Therapy Manufacturing Quality Control Market

Figure 4: Global Cell and Gene Therapy Manufacturing Quality Control Market: Drivers

Figure 5: Global Cell and Gene Therapy Manufacturing Quality Control Market: Challenges

Figure 6: Global Cell and Gene Therapy Manufacturing Quality Control Market: Trends

Figure 7: Global Cell and Gene Therapy Manufacturing Quality Control Market: Opportunity

Figure 8: Global Cell and Gene Therapy Manufacturing Quality Control Market: Restraint

Figure 9: Global Cell and Gene Therapy Manufacturing Quality Control Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Cell and Gene Therapy Manufacturing Quality Control Market Value (USD Million) By Region

Figure 15: Global Cell and Gene Therapy Manufacturing Quality Control Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Cell and Gene Therapy Manufacturing Quality Control Market Value (USD Million) By Region

Figure 23: Global Cell and Gene Therapy Manufacturing Quality Control Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global Cell and Gene Therapy Manufacturing Quality Control Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Cell and Gene Therapy Manufacturing Quality Control Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Cell and Gene Therapy Manufacturing Quality Control Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Cell and Gene Therapy Manufacturing Quality Control Market Value (USD Million) By Region

Table 10: Global Cell and Gene Therapy Manufacturing Quality Control Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Cell and Gene Therapy Manufacturing Quality Control Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Cell and Gene Therapy Manufacturing Quality Control Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Cell and Gene Therapy Manufacturing Quality Control Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Bio-Rad Laboratories, Inc. Basic Information And Sales Area

Table 31: Bio-Rad Laboratories, Inc.. Products Portfolio

Table 32: QIAGEN Basic Information And Sales Area

Table 33: QIAGEN. Products Portfolio

Table 34: Charles River Laboratories International, Inc. Basic Information And Sales Area

Table 35: Charles River Laboratories International, Inc.. Products Portfolio

Table 36: Lonza Group AG Basic Information And Sales Area

Table 37: Lonza Group AG. Products Portfolio

Table 38: Bio-Techne Corporation Basic Information And Sales Area

Table 39: Bio-Techne Corporation. Products Portfolio

Table 40: Merck KGaA Basic Information And Sales Area

Table 41: Merck KGaA. Products Portfolio

Table 42: F. Hoffmann-La Roche Ltd Basic Information And Sales Area

Table 43: F. Hoffmann-La Roche Ltd. Products Portfolio

Table 44: Thermo Fisher Scientific, Inc. Basic Information And Sales Area

Table 45: Thermo Fisher Scientific, Inc.. Products Portfolio

Table 46: Intertek Group Plc Basic Information And Sales Area

Table 47: Intertek Group Plc. Products Portfolio

Table 48: Eurofins Scientific S.E. Basic Information And Sales Area

Table 49: Eurofins Scientific S.E.. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Type

Table 51: Global Market Share (%) By Type (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Application

Table 53: Global Market Share (%) By Application (2032)

Table 54: Global Cell and Gene Therapy Manufacturing Quality Control Market Value (USD Million) By Region

Table 55: Global Cell and Gene Therapy Manufacturing Quality Control Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Type

Table 58: North America Market Value (USD Million) (2025-2032) By Application

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Type

Table 61: Europe Market Value (USD Million) (2025-2032) By Application

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Type

Table 67: South America Market Value (USD Million) (2025-2032) By Application

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

FAQs

1. What is the current Cell and Gene Therapy Manufacturing Quality Control market size?

The Cell and Gene Therapy Manufacturing Quality Control market size was estimated at roughly USD 1.3 billion in 2023, reflecting heightened investment in advanced analytical platforms, rising product pipelines, and increasing demand for stringent release testing across global biopharma manufacturers.

2. What is the projected growth forecast for the market?

The market is projected to expand at a compound annual growth rate of 7.2 % between 2024 and 2032, reaching an estimated USD 2.5 billion by the end of the forecast period, driven by expanding CAR‑T and AAV pipelines.

3. Which factors are the key drivers behind market expansion?

Key drivers include escalating regulatory expectations for product consistency, the surge in personalized cell therapies requiring rapid batch release, and the adoption of high‑throughput sequencing and mass‑spectrometry tools that enhance assay sensitivity and reduce time‑to‑market.

4. What are the main challenges facing manufacturers?

Major challenges stem from the high cost of qualified reference standards, limited scalability of legacy QC assays, data‑integration complexities across fragmented platforms, and a shortage of skilled analysts capable of interpreting multi‑omics datasets within tight release windows.

5. Which regions lead the Cell and Gene Therapy Manufacturing Quality Control market?

North America remains the regional leader, accounting for over 45 % of total revenue, propelled by the United States' robust biotech ecosystem; Europe follows with strong governmental funding, while Asia‑Pacific shows the fastest CAGR, driven by China’s expanding cell‑therapy manufacturing base.

6. Who are the top companies operating in this space?

Leading firms include Thermo Fisher Scientific, Merck KGaA, Danaher Corporation, Bio‑Rad Laboratories, and Agilent Technologies, each offering integrated QC suites that combine chromatography, spectroscopy, and digital workflow solutions to meet escalating assay complexity and compliance demands.

7. What future opportunities are emerging for the market?

Future outlook highlights opportunities in AI‑driven predictive QC, decentralized point‑of‑care release testing, and modular microfluidic platforms that enable on‑demand assay execution, potentially lowering costs and accelerating commercialization of next‑generation gene‑editing therapies across multiple therapeutic areas.

8. How is technology reshaping quality control processes?

The integration of real‑time process analytical technology (PAT) and cloud‑based LIMS is reshaping QC workflows, allowing continuous monitoring, rapid data analytics, and remote auditability, which collectively improve batch release speed while maintaining regulatory compliance throughout the product lifecycle.

9. What is the current regulatory landscape for quality control?

Regulators such as the FDA and EMA are issuing more detailed guidance on assay validation, data integrity, and risk‑based QC, prompting manufacturers to adopt harmonized standards, invest in robust documentation systems, and engage early with authorities to mitigate approval delays.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Cell and Gene Therapy Manufacturing Quality Control Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.50 billion
Revenue forecast in 2033	6.41 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bio-Rad Laboratories, Inc.; QIAGEN; Charles River Laboratories International, Inc.; Lonza Group AG; Bio-Techne Corporation; Merck KGaA; F. Hoffmann-La Roche Ltd; Thermo Fisher Scientific, Inc.; Intertek Group Plc; Eurofins Scientific S.E.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options